drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate targeting HER2: the trastuzumab antibody binds HER2, inhibits signaling and can trigger ADCC; after internalization it releases the DXd payload, a membrane-permeable topoisomerase I inhibitor that induces DNA damage and bystander killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Trastuzumab deruxtecan is an anti-HER2 antibody–drug conjugate: trastuzumab binds HER2, inhibits signaling and can trigger ADCC; after internalization a cleavable linker releases the DXd payload, a membrane-permeable topoisomerase I inhibitor that causes DNA damage and cell death with a bystander effect.
drug_name
Trastuzumab deruxtecan (T-DXd, DS-8201a)
nct_id_drug_ref
NCT06088056